Hua et al. 6 reported that the blockade of IGF-IR might counteract the Imatinib resistance of CML cells, and so this therapeutic strategy appears to be effective in the treatment of patients with CML, particularly during the aggressive stages or in cases resistant to Imatinib. Here, IGF1R is linked to chronic myelogenous leukemia, BCR-ABL1 positive.